Transplante hepático: variação dos níveis sanguíneos de tacrolimo e desfechos de sobrevida, rejeição e óbito / Liver transplantation: tacrolimus blood levels variation and survival, rejection and death outcomes

ABSTRACT BACKGROUND: Immunosuppressive drugs have important role in transplant of solid grafts, it aim avoid episodes of acute and chronic rejection and improving graft survival and patient survival. In Brazil, in 2016, liver transplantation was the third most frequent, with 1,880 transplants performed, of which 150 in Rio Grande do Sul. Several studies evaluated the association between variability in blood levels of immunosuppressive tacrolimus and late acute cellular graft rejection. OBJECTIVE: To investigate the association of tacrolimus blood levels with clinical outcomes late acute cellular rejection, death, patient survival and graft survival in patients undergoing liver transplantation. METHODS: This is a retrospective longitudinal study including patients submitted to adult liver transplantation by the Liver Transplantation Group in the Santa Casa de Misericórdia Hospital of Porto Alegre, from January 2006 to January 2013, and who used tacrolimus as immunosuppressive therapy. RESULTS: Of the 127 patients included in the study, the majority were male (70.1%), 52-60 years old (33.9%) at the transplant. The most frequent causes of liver transplantation in this series were hepatitis C virus and hepatocellular carcinoma (24.4%) and alcohol (15.7%). Thirteen patients had late acute cellular rejection (10.2%); of these, three had two episodes. Regarding severity classification, seven patients had mild late acute cellular rejection. The mean time of rejection after liver transplantation was 14 months (ranging from 8 to 33 months). Overall survival was 8.98 years. Regarding tacrolimus blood levels, 52 patients with a variation ≥2 standard deviations were identified. Of these patients, eight had rejection; however, the association was not significant (P=0.146). A significant association was found between variation ≥2 standard deviations in tacrolimus blood levels and death (P=0.023) and survival (P=0.019). Regarding 5-year follow-up of graft survival, being two standard deviations above increases by 2.26 times the risk of transplanted graft loss, and for each unit of increase of standard deviation of tacrolimus blood levels there is a two-fold increase in the risk of graft loss in 5 years. CONCLUSION: Increased risk of graft loss associated with increased standard deviations of tacrolimus blood levels may indicate the need for more rigorous and prospective monitoring of tacrolimus blood levels.

RESUMO CONTEXTO: Os imunossupressores desempenham importante papel no transplante de órgãos sólidos, com o objetivo de evitar a rejeição aguda e crônica, aumentando o tempo de sobrevida do órgão e do paciente. No Brasil, em 2016, o transplante de fígado foi o 3° mais frequente, com um número de 1.880 transplantes, sendo 150 realizados no Rio Grande do Sul. OBJETIVO: Investigar a associação da variação dos níveis sanguíneos de tacrolimo com os desfechos clínicos, rejeição celular aguda tardia, óbito, sobrevida de paciente e enxerto em pacientes submetidos ao transplante hepático. MÉTODOS: Trata-se de um estudo longitudinal retrospectivo, no qual foram incluídos os pacientes submetidos ao transplante hepático adulto pelo grupo de transplante hepático na Irmandade Santa Casa de Misericórdia de Porto Alegre, no período de janeiro de 2006 a janeiro de 2013, e que fizeram o uso de tacrolimo como terapia imunossupressora. RESULTADOS: Dos 127 pacientes incluídos no estudo, a maioria era do gênero masculino (70,1%), caucasiana (86,4%), com idade entre 52 e 60 anos (33,9%). As associações de causas mais frequentes para transplante hepático foram vírus da hepatite C, carcinoma hepatocelular (24,4%) e álcool (15,7%). Um total de treze pacientes apresentaram rejeição celular aguda tardia (10,2%); destes, três tiveram dois episódios. O tempo médio de rejeição após o transplante hepático foi de 14 meses, variando de 8 a 33 meses. A sobrevida global foi de 8,98 anos. Em relação aos níveis sanguíneos de tacrolimo, foram identificados 52 pacientes com uma variação maior ou igual a dois desvios-padrão. Destes pacientes, oito tiveram rejeição, contudo, a associação não foi significativa (P=0,146). Foi encontrada uma associação significativa entre a variação maior ou igual a dois desvios-padrão nos níveis sanguíneos de tacrolimo com óbito (P=0,023) e sobrevida (P=0,019). Em relação ao acompanhamento de sobrevida do enxerto em cinco anos, estar dois desvios-padrão acima aumenta em 2,26 vezes o risco de perda do enxerto transplantado, e a cada unidade de aumento de desvio-padrão dos níveis sanguíneos de tacrolimo há um aumento de duas vezes no risco de perda do enxerto transplantado em 5 anos. CONCLUSÃO: O aumento do risco da perda do enxerto associado ao aumento da variação dos níveis sanguíneos de tacrolimo pode indicar a necessidade do acompanhamento mais rigoroso e prospectivo dos níveis sanguíneos de tacrolimo.

Biliary complications after liver transplantation / Complicações biliares pós-transplante hepático

ABSTRACT Background: Biliary reconstitution has been considered the Achilles's heel of liver transplantations due to its high rate of postoperative complications. Aim: To evaluate the risk factors for occurrence of biliary strictures and leakages, and the most efficient methods for their treatment. Method: Of 310 patients who underwent liver transplantation between 2001 and 2015, 182 medical records were retrospectively analyzed. Evaluated factors included demographic profile, type of transplantation and biliary reconstitution, presence of vascular and biliary complications, their treatment and results. Results: 153 (84.07%) deceased donor and 29 (15.93%) living donor transplantations were performed. Biliary complications occurred in 49 patients (26.92%): 28 strictures (15.38%), 14 leakages (7.7%) and seven leakages followed by strictures (3.85%). Hepatic artery thrombosis was present in 10 patients with biliary complications (20.4%; p=0,003). Percutaneous and endoscopic interventional procedures (including balloon dilation and stent insertion) were the treatment of choice for biliary complications. In case of radiological or endoscopic treatment failure, surgical intervention was performed (biliodigestive derivation or retransplantation (32.65%). Complications occurred in 25% of patients treated with endoscopic or percutaneous procedures and in 42.86% of patients reoperated. Success was achieved in 45% of patients who underwent endoscopic or percutaneous procedures and in 61.9% of those who underwent surgery. Conclusion: Biliary complications are frequent events after liver transplantation. They often require new interventions: endoscopic and percutaneous procedures at first and surgical treatment when needed. Hepatic artery thrombosis increases the number of biliary complications.

RESUMO Racional: A reconstituição biliar é considerada o calcanhar-de-Aquiles do transplante hepático devido à sua elevada taxa de complicações pós-operatórias. Objetivo: Analisar os fatores de risco para ocorrência de estenoses e fístulas biliares e os métodos terapêuticos mais eficientes para seu tratamento. Método: De 310 pacientes transplantados entre 2001 e 2015, 182 prontuários foram analisados retrospectivamente. Foram avaliados o perfil demográfico dos pacientes, tipo de transplante e reconstituição biliar, presença de complicações biliares e vasculares, tratamento utilizado e seus resultados. Resultados: Foram realizados 153 (84,07%) transplantes hepáticos cadavéricos e 29 intervivos (15,93%). Complicações biliares ocorreram em 49 pacientes (26,92%): 28 estenoses (15,38%), 14 fístulas (7,7%) e sete fístulas seguidas de estenose (3,85%). Trombose de artéria hepática esteve presente em 10 pacientes com complicações biliares (20,4%, p=0,003). Os tratamentos de escolha foram os procedimentos endoscópicos ou percutâneos (incluindo dilatação por balão e colocação de próteses (40,82%). No insucesso deles, foi realizado tratamento cirúrgico (derivação biliodigestiva ou retransplante (32,65%). Complicações ocorreram em 25% dos pacientes que fizeram procedimentos endoscópicos ou percutâneos e em 42,86% dos submetidos ao tratamento cirúrgico. A resolução das complicações biliares foi de 45% com os procedimentos endoscópicos ou percutâneos e de 61,9% com o cirúrgico. Conclusão: Complicações biliares são frequentes após transplante hepático. Comumente requerem novas intervenções. Os procedimentos endoscópicos e percutâneos são a primeira escolha e os cirúrgicos, empregados na falha destes. Trombose de artéria hepática aumenta a incidência de complicações biliares.

Trasplante hepático en mayores de 65 años de edad: experiencia en el Hospital Pablo Tobón Uribe, Medellín, Colombia 2004-2010 / Experience with Liver Transplantation in patients over 65 years of Age at the Hospital Pablo Tobón Uribe in Medellin, Colombia from 2004 to 2010

El trasplante hepático se ha extendido a personas mayores de 65 años de edad, quienes anteriormente eran excluidas de los protocolos debido a la mayor morbilidad y mortalidad asociadas con la edad. Este estudio tuvo como objetivo identificar la supervivencia y las complicaciones en pacientes mayores de 65 años de edad sometidos a trasplante de hígado. Se analizaron historias clínicas de pacientes mayores de 65 años de edad trasplantados en el período comprendido entre septiembre de 2004 y noviembre de 2010, en el Hospital Pablo Tobón Uribe de Medellín, Colombia. Se estudiaron 27 pacientes con una edad promedio de 67 años. La supervivencia postrasplante en ellos fue del 85,2%, 70,4% y 63% a los 30 días, al año y a los 5 años, respectivamente. Se evaluaron las complicaciones postrasplante, siendo las más frecuentes el sangrado masivo y las infecciones nosocomiales. La principal causa de muerte fueron los eventos cardiovasculares. En conclusión, la selección adecuada de los pacientes permite a aquellas personas mayores de 65 años convertirse en candidatos a trasplante hepático, con una buena supervivencia actuarial a 5 años y una mejor calidad de vida.

Liver transplantation protocols have been extended to people over 65 years of age who had previously been excluded from protocols due to the increased morbidity and mortality rates associated with age. This study aims to identify survival rates and complications in patients over 65 years who have undergone liver transplantation. Medical records of patients older than 65 who underwent liver transplantation in the period between September 2004 and November 2010 at the Hospital Pablo Tobón Uribe in Medellin, Colombia were analyzed. We studied 27 patients with an average age of 67 years. The 30 day post-transplant survival rate was 85.2%, at one year the survival rate was 70.4%, and at five years it was 63%. An evaluation of post-transplant complications found that the most frequent complications were massive bleeding and nosocomial infections. The main causes of death were cardiovascular events. Conclusion: Proper patient selection allows those over 65 years of age to become candidates for liver transplantation with a good actuarial 5-year survival rate and better quality of life.

Incidência e aspectos de imagem do linfoma pós-transplante hepático em crianças / Incidence and imaging findings of lymphoma after liver transplantation in children

OBJETIVO: Avaliar a incidência e os aspectos de imagem do linfoma pós-transplante hepático em crianças. MATERIAIS E MÉTODOS: Foram revisados os prontuários e exames de imagem de crianças submetidas a transplante hepático entre 2000 e 2008 em uma única instituição. RESULTADOS: De 241 crianças submetidas a transplante hepático, com seguimento médio de 41,4 ± 26,4 meses, 16 (6,6 por cento) tiveram linfoma. A média de idade no transplante hepático das crianças que desenvolveram linfoma foi inferior à das crianças que não desenvolveram (23,9 ± 18,9 vs. 38,0 ± 48,9 meses; p = 0,02). O tempo entre o transplante e o desenvolvimento do linfoma variou de 6 a 103 meses. A apresentação clínica e radiológica foi variável e a localização mais comum do tumor foi no abdome (n = 13; 81,3 por cento), seguida de tórax e cabeça e pescoço (n = 4; 25,0 por cento cada). Os achados de imagem incluíram: linfonodomegalias, massas mediastinais, pulmonares e mesentéricas, espessamento parietal de alças intestinais e nódulos hepáticos e renais. Quatro crianças (25,0 por cento) faleceram devido a complicações do linfoma. CONCLUSÃO: Linfomas são complicações relativamente incomuns e potencialmente fatais que podem acontecer a qualquer momento após o transplante hepático em crianças, e que têm diversas apresentações clínicas e de imagem.

OBJECTIVE: To evaluate the incidence and imaging findings of lymphoma after liver transplantation in children. MATERIALS AND METHODS: The authors reviewed records and imaging studies of children submitted to liver transplantation in the period between 2000 and 2008 in a single institution. RESULTS: Among 241 children submitted to liver transplantation, with a mean follow-up period of 41.4 ± 26.4 months, 16 (6.6 percent) had lymphoma. The mean age of the patients who developed lymphoma at the moment of transplantation was lower than in children who did not develop malignancy (23.9 ± 18.9 versus 38.0 ± 48.9 months; p = 0.02). The time interval between liver transplantation and the diagnosis of lymphoma ranged from 6 to 103 months. Clinical and radiological presentation was variable and the abdomen was the most common location of the tumor (n = 13; 81.3 percent), followed by chest and head and neck (n = 4; 25.0 percent each). Imaging findings included adenopathy, mediastinal, pulmonary and mesenteric masses, bowel wall thickening and hepatic and renal nodules. Four children (25.0 percent) died because of complications of lymphoma. CONCLUSION: Lymphomas are relatively uncommon and potentially fatal complications that may occur any time after pediatric liver transplantation, presenting different clinical and imaging findings.

Artificial Liver Devices and Bioartificial Liver Systems: Current Status / 대한이식학회지

Acute liver failure is a rapidly progressive disease of the liver associated with high morbidity and mortality without liver transplantation. Although good survival after transplantation can be achieved, due to the disparity between patients awaiting transplantation and available organs, many patients die due to progression of the disease while waiting for a liver graft. To reduce the high morbidity and mortality associated with acute liver failure, attempts have been made during the last several decades to develop a temporary liver support system, such as artificial and bioartificial livers. The artificial liver is a non-biological device mainly aimed at the removal of accumulated toxins during liver failure, and the bioartificial liver is a biological device that has bioreactors containing living hepatocytes which provide both biotransformation and synthetic liver functions. There are currently 3 artificial livers available in the market that have been actively used in the clinical field, and 11 bioartificial livers that have been developed and have undergone clinical trials. In this article, we will discuss about the 3 artificial liver devices and 5 bioartificial liver systems that are the most advanced and have been widely evaluated clinically. Also, the characteristics and the preclinical data of the first bioartificial liver system developed in Korea that is currently under clinical investigation, will be discussed.

Health-related quality of life of Filipino pediatric liver transplant recipients and children with chronic liver disease using PedsQL4.0™ Tagalog version

BACKGROUND: The Pediatric Quality of Life (PedsQL4.0TM) scale has been shown to be reliable and valid in assessing health related quality of life (HRQOL). However, its Tagalog version has not been field-tested. OBJECTIVES: To determine the reliability and validity of the PedsQL4.0TM Tagalog version and to compare the HRQOL of Filipino liver transplant (LT) recipients, children with chronic liver disease (CLD) and healthy controls. METHODOLOGY: This is a cross-sectional study that included Filipinos 2-18 years who had undergone LT and those with CLD. PedsQL4.0TM Tagalog version was administered as a proxy-report for caregivers and child-report for children >5 years. RESULTS: 237 PedsQL4.0 questionnaires were completed. Reliability was demonstrated for psychosocial (Cronbach =0.86-0.88), physical ( =0.86-0.88) and total ( =0.89-0.92) health summary scores. Construct validity showed a medium to large effect size (0.39-1.34) between patients and controls. No difference was noted on the total health summary scores and the individual domains between LT recipients and controls while the scores of patients with CLD were significantly lower compared to LT recipients and healthy subjects. CONCLUSIONS: The PedsQL4.0TM Tagalog version is a valid and reliable HRQOL tool. The HRQOL of LT recipients is similar to healthy children while CLD patients had poorer HRQOL.

10 años de trasplante hepático en el Perú / 10 years of liver transplantation in Peru

El artículo revisa la experiencia única en el Perú de 10 años de trasplantes realizada por el departamento de trasplantes del Hospital Nacional Guillermo Almenara Irigoyen (HNGAI), describiendo la historia, resultados quirúrgicos en adultos y niños, retrasplantes, trasplantes combinados hígado-riñon, las diferentes complicaciones encontradas y toda la experiencia recogida en los 72 trasplantes realizados hasta la presentación de este artículo.

The article reviews the experience in 10 years of hepatic transplants performed by The Transplant Department of the National Hospital Guillermo Almenara Irigoyen (HNGAI), describing the history, surgical outcomes in adults and children, retransplantation, combined liver-kidney transplants, complications in 72 transplants performed at the time of submission of the article.

Síndrome hepatopulmonar y trasplante hepático / Hepatopulmonary syndrome and liver transplantation

El síndrome hepatopulmonar es una entidad clínica que compromete seseramente el estado funcional de los pacientes con enfermedad hepática en estado terminal. No se puede predecir con exactitud la historia natural de este esndrome una veZ ha sido diagnosticado. Sin embargo se reconoce que queronóstico es grave, lentamente progresivo y aunque la causa de muerte suele estar relacionada a la enfermedad depática, la calidad de vida de estos pacientes se se notablemente alterada por el trastornoventilatorio asoccado. Se considera que el trasplante hepático, en casos bien seleccionados, puede logralla completa resolución de este síndrome y el éxito en elmanejo perioperatorioestá directamente relacionado con el cococimiento de la fisiopatología.

Hepatopulmonary syndrome is a clinical entiy that severely impairs functional status of patients with end stage liver disease. Natural lourse of this syndrome is unpredictable once ii has beeeniagnosed. Hotuevev it is known that its prognosisis seúous, slowly progressive and although cause of death is often related to liver disease, quality of Ufe in these patients ii significantly impaired by yhe additional ventilatory disorder. It is actually considered that liver transplantation, in selected cases, can lead to complete tesolution on this syndrome and so soccess in the peúoperative management is tisectly related to the knotuledge of the pathophysiology process.

Transplante de fígado / Liver transplantation

Os progressos na preservação dos órgãos, na técnica cirúrgica e nos cuidados do pós-operatório permitiram o desenvolvimento do transplante de fígado. A aplicabilidade dessa alternativa terapêutica foi além das complicações da doença hepática crônica que ameaça a vida, e hoje inclui as doenças incapacitantes e os problemas relacionados à qualidade de vida. São elementos-chaves no transplante de fígado o encaminhamento precoce ao centro especializado e a identificação do melhor momento para o procedimento. O resultado pós-transplante hepático vai depender da intensidade da doença e do grau de descompensação pré-operatória.

The horizons for liver transplantation continue to evolve and expand. The advances over the past decade have been spectacular. Improved liver preservation made long distance organ procurement and less time-sensitive transplant procedures feasible. The decision process for patient selection and timing for liver transplantation is complex and incorporates multiple factors: survival rates, morbidities, resource utilization, and quality of life. Advances not only in surgical technique and immunosupression but also in immediate postoperative management are responsible for the substantial improvement in outcome that have occurred over the last three decades.

Fatores de risco e conduta nas complicações do trato biliar no transplante hepático / Risk factors and management of biliary tract complications in liver transplantation

A reconstrução biliar é um dos pontos vulneráveis do transplante hepático apresentando incidência de complicações biliares, variando de 10 a 35%, nos diversos estudos da literatura. Esse trabalho tem por objetivo apresentar a experiência do nosso serviço em relação à incidência e ao manejo das complicações biliares notransplante de fígado. Foram incluídos no estudo 147 transplantes hepáticos ortotópicos, com idade média de 37,3 anos, correspondendo a 88 procedimentos em pacientes do sexo masculino e 59 do sexo feminino. Complicações biliares ocorreram em 27 transplantes (18,36%) em 25 pacientes (dois retransplantes). A presença derejeição celular e de complicações vasculares foi identificada como fator de risco para as complicações biliares.A idade, o sexo, a etiologia da cirrose e a técnica utilizada na reconstrução biliar não foram fatores de risco. No total, foram empregados 52 cursos terapêuticos: tratamento cirúrgico em 23 vezes; tratamento endoscópico em15 vezes; retransplante em sete vezes; drenagem biliar transparieto-hepática em seis vezes e um paciente está emlista de espera para retransplante. Conclui-se deste estudo que as complicações biliares são freqüentes após o transplante hepático e que as vasculares e a rejeição celular são fatores de risco.

Biliary reconstruction is a vulnerable step of liver transplantation, presenting an incidence of biliary complicationsbetween 10 to 35% in many studies. Our aim is to present our incidence and treatment of biliary complications, in atotal of 147 orthotopic liver transplantations, 88 males and 59 females, with an mean age of 37 years. Biliary complications occurred in 27 transplants (18,36%) performed in 25 patients (two retransplants). Cellular rejection and vascular complications were identified as risk factors for biliary complications. Age, sex, etiology of cirrhosis and biliary reconstruction technique were not risk factors. Fifty-two therapeutic courses were performed: 23 surgical treatments, 15 endoscopic treatments, seven retransplants, six external biliary drainage and one patient is waitingretransplantation. In conclusion, biliary complications are frequent after liver transplantation and vascular complications and cellular rejection are risk factors for them.

Complicações vasculares pós-transplante hepático / Vascular complications after liver transplantation

Objetivo: O objetivo do estudo é apresentar as complicações vasculares arteriais e venosas observadas em um serviço de transplante hepático universitário brasileiro. Métodos: Os prontuários de todos os pacientes submetidos a transplante hepático no período de setembro de 1991 a janeiro de 2000 foram analisados para determinar as complicações vasculares e correlacioná-las a dados clínicos e do procedimento cirúrgico. Resultados:Foram realizados 169 transplantes, sendo quatro inter vivos e nove retransplantes. Um total de 24 complicações vasculares (14,3%) foi identificado em 22 pacientes (13,0%). A complicação vascular mais comum foi atrombose da artéria hepática (15 casos), seguido da trombose da veia porta (quatro casos). Complicações da veia cava inferior infra ou supra-hepática foram incomuns, ocorrendo em um total de três casos (1,8%). As complicações vasculares foram mais freqüentes nas crianças (26,06%) do que em adultos (13,14%) (p<0,05). Dos pacientes com trombose da artéria hepática, um foi submetido à angioplastia, um a trombectomia, oito a retransplante e cinco evoluíram para o óbito enquanto aguardavam retransplante. Dos quatro casos de trombose da veia porta, dois foram a óbito, um foi submetido à colocação percutânea de prótese e um a tratamento conservador. Os pacientescom estenose da veia porta e da veia cava inferior infra e supra-hepática foram submetidos a tratamento conservador, com boa evolução clínica. Conclusões: que as complicações vasculares são freqüentes após o transplante hepático, principalmente em crianças, e são associadas à elevada morbidade, mortalidade e retransplante.

Background: The authors present the vascular complications observed in an academic Brazilian hepatic transplantation division. Methods: Hospital charts of all patients who were submitted to a liver transplantation between of September 1991 and January 2000, were evaluated to determine vascular complications and to correlated them to clinical data and surgical procedures. Results: Of a total of 169 tranplantations performed, four were from living related donors and 9 retransplantations. Twenty-four vascular complications (14,3%) were identified in 22 patients (13,0%), the most common being hepatic artery thrombosis (15 cases) and portal vein thrombosis (4 cases). Complications of the infra and suprahepatic vena cava were observed in three cases (1,8%). Vascular complications were more common in children (26,06%) than in adults (13,14%) (p<0,05). From the patients with hepatic artery thrombosis, one was submitted to an angioplasty, one to a thrombectomy, while eight underwent retransplantation and five died waiting for retransplantation. Of the patients with portal vein thrombosis, two died, one submitted to an endovascular stent placement, and one to conservative treatment. Patients with stenosis of the portal vein and of the infra and suprahepatic inferior vena cava received a conservative treatment, with good clinical recovery. Conclusion: Vascular complications are frequent after liver transplantation, mainly withchildren. They are associated with an elevated rate of morbidity, mortality and retransplantation.

Pseudo-obstruction of the Portal Vein in Hepatic Transplantation and Liver Resection: Case Reports / 한국간담췌외과학회지

Confirmation of patency of the portal vein by either ultrasound or angiography is important for evaluating patients considered for living-related liver transplant(LRLT) and liver resection(LR). Portal vein thrombosis(PVT) in LRLT necessitates planning for a technically difficult operation because consideration must be given to obtaining an alternative for splanchnic inflow. When performing LR for hepatocellular carcinoma(HCC), portal vein tumor thrombus was usually thought of as a poor prognositic factor for tumor recurrence. Recently, we experienced two cases of pseudo-obstruction of the portal vein, one in LRLT and the other in LR. In the case of LRLT, a 16-month-old female patient was diagnosed as congenital biliary atresia. PVT had been preoperatively suggested, but the vein was actually open. The patient was successfully transplanted using the left lateral segment of the donor with ordinary portal vein anastomosis and the postoperative course was uneventful except for mild acute rejection episodes. In the case of LR, a 60-year-old male patient presented with incidental symptoms. Preoperative ultrasonography, computed tomography, and angiography showed a 9x8cm-sized mass in the right lobe of the liver with obstruction of the right portal vein, which suggested tumor thrombus. However, the operation disclosed the patency of the portal vein and a right lobectomy was subsequently done. Because of the scanty blood flow of the portal vein due to arterio-portal shunt, PVT was preoperatively suggested. Our experience indicates that more sophisticated image studies are needed for evaluating portal vein patency in the patient who needs hepatic transplant as well as liver resection, and that the surgeon should not hesitate to procede to operative procedures even though conventional studies suggest PVT.